A Public Offering Undercut This Biotech Stock's Promising Cancer DataInvestors Business Daily • 05/28/20
Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced MelanomaGlobeNewsWire • 05/27/20
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced MelanomaGlobeNewsWire • 05/13/20
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/06/20
Do Options Traders Know Something About Iovance Biotherapeutics (IOVA) Stock We Don't?Zacks Investment Research • 04/17/20
Are Options Traders Betting on a Big Move in Iovance Biotherapeutics (IOVA) Stock?Zacks Investment Research • 03/11/20
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with LifileucelGlobeNewsWire • 01/15/20
Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 AnalogGlobeNewsWire • 01/12/20
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License AgreementGlobeNewsWire • 01/12/20